Glomerulonephritis, IGA: Clinical Trials

273 trials for Glomerulonephritis, IGA, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

92 completed, 65 recruiting, 36 unknown, 30 not yet recruiting. 83 Phase 2, 51 Phase 3, 36 Not applicable, 32 Phase 4, 24 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 283Completed 25, Recruiting 20, Not yet recruiting 11, Terminated 11, Active not recruiting 6, Unknown 6, Enrolling by invitation 2, Withdrawn 2
Phase 351Completed 13, Recruiting 11, Active not recruiting 9, Unknown 6, Not yet recruiting 5, Terminated 3, Enrolling by invitation 2, Withdrawn 2
Not applicable36Completed 16, Unknown 8, Recruiting 6, Not yet recruiting 3, Suspended 1, Terminated 1, Withdrawn 1
Phase 432Completed 12, Unknown 10, Recruiting 4, Not yet recruiting 3, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 124Completed 12, Recruiting 5, Active not recruiting 3, Not yet recruiting 3, Terminated 1
Early Phase 112Recruiting 5, Not yet recruiting 4, Enrolling by invitation 2, Withdrawn 1

Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
NM8074 - IgA Nephropathy
Phase 2Not yet recruitingNovelMed Therapeutics102028-02-012026-04-13
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy
Early Phase 1Not yet recruitingGrit Biotechnology302027-08-012026-09-11
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
Obinutuzumab Beta - Primary IgA Nephropathy
Phase 4Not yet recruitingRuijin Hospital202026-12-102026-10-22
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN)
Phase 3Not yet recruitingNovartis Pharmaceuticals3402026-12-012026-09-30
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
JADE101, Placebo - IgA Nephropathy (IgAN)
Phase 3RecruitingJade Biosciences, Inc.4802026-12-012026-11-03
MYTP01 for Immune-Mediated Diseases
MYTP01, MYTP01 Placebo - IgA Nephropathy, Kidney Transplant Recipients
Not applicableNot yet recruitingZhejiang Provincial People's Hospital1602026-12-012026-11-04
A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)
Felzartamab - Immunoglobulin A Nephropathy
Phase 2Not yet recruitingBiogen252026-11-162026-10-22
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN)
Phase 2Recruitingargenx1202026-11-052026-10-27
A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions
Budesonide delayed release tablet 4mg, Budesonide Delayed Release Capsules, Budesonide delayed release tablet 16mg - IgA Nephropathy (IgAN)
Phase 1Active not recruitingTriastek, lnc.182026-11-032026-11-09
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
Sibeprenlimab, Standard of care - IgA Nephropathy
Phase 3Not yet recruitingOtsuka Pharmaceutical Development & Commercialization, Inc.242026-10-302026-10-15
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy
Phase 3Not yet recruitingVertex Pharmaceuticals Incorporated402026-10-232026-10-22
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN)
Phase 1Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.1002026-10-152026-10-21
Mediators of Loin Pain in IgA Nephropathy
IgA Nephropathy (IgAN)
Enrolling by invitationUniversity of Leicester402026-10-132026-10-20
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
Budesonide delayed release tablet - IgA Nephropathy
Phase 1Not yet recruitingTriastek, lnc.182026-10-012026-10-27
Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study
IgA Nephropathy (IgAN), IgA Vasculitis
RecruitingPediatric Nephrology Research Consortium10002026-10-012026-11-12
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Phase 4Not yet recruitingUniversity of Illinois at Chicago202026-09-292026-09-21
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Povetacicept - Immunoglobulin A Nephropathy
Phase 3Enrolling by invitationVertex Pharmaceuticals Incorporated6052026-09-172026-10-19
Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy
Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy
Phase 2Not yet recruitingShaheed Suhrawardy Medical College and Hospital1042026-09-012026-08-25
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
Universal STAR-T Cell - IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Not applicableNot yet recruitingGuangdong Provincial People's Hospital242026-08-312026-08-10
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
Gd-IgA1 monitoring - IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis
Not applicableRecruitingHong Zhang3742026-08-242026-09-16

Showing 20 of 273. Sign in to see all of them.

Narrower conditions

Proteinuria (39)  ·  Kidney Diseases (31)  ·  Glomerulonephritis (27)  ·  Renal Insufficiency, Chronic (23)  ·  Glomerulonephritis, Membranous (19)  ·  Glomerulosclerosis, Focal Segmental (18)  ·  Diabetic Nephropathies (14)  ·  Autoimmune Diseases (13)  ·  Lupus Nephritis (13)  ·  Nephrosis, Lipoid (13)  ·  Urologic Diseases (12)  ·  Nephritis (9)  ·  Nephrotic Syndrome (9)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8)

Broader conditions

Female Urogenital Diseases (272)  ·  Female Urogenital Diseases and Pregnancy Complications (272)  ·  Male Urogenital Diseases (272)  ·  Urogenital Diseases (267)  ·  Immune System Diseases (265)  ·  Nephritis (264)  ·  Urologic Diseases (261)  ·  Autoimmune Diseases (260)  ·  Glomerulonephritis (246)  ·  Kidney Diseases (242)  ·  Pathological Conditions, Signs and Symptoms (73)  ·  Signs and Symptoms (46)  ·  Pathologic Processes (43)  ·  Urination Disorders (41)  ·  Urological Manifestations (40)

Interventions

Prednisone (14)  ·  Mycophenolic Acid (13)  ·  Prednisolone (11)  ·  Atrasentan (8)  ·  telitacicept (8)  ·  Adrenal Cortex Hormones (6)  ·  Angiotensin-Converting Enzyme Inhibitors (6)  ·  Losartan (6)  ·  Methylprednisolone (6)  ·  sparsentan (6)  ·  Cyclophosphamide (5)  ·  TACI receptor-IgG Fc fragment fusion protein (5)  ·  iptacopan (5)  ·  Blood Specimen Collection (4)  ·  Budesonide (4)

Sponsors

Novartis Pharmaceuticals (18)  ·  Guangdong Provincial People's Hospital (7)  ·  Sun Yat-sen University (7)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (6)  ·  Alexion Pharmaceuticals, Inc. (5)  ·  Calliditas Therapeutics AB (5)  ·  Peking University First Hospital (5)  ·  Ruijin Hospital (5)  ·  The Children's Hospital of Zhejiang University School of Medicine (5)  ·  Travere Therapeutics, Inc. (5)  ·  Centre Hospitalier Universitaire de Saint Etienne (4)  ·  Chengdu Suncadia Medicine Co., Ltd. (4)  ·  Vera Therapeutics, Inc. (4)  ·  Air Force Military Medical University, China (3)  ·  Assistance Publique - HĂ´pitaux de Paris (3)

Countries

China (126)  ·  United States (73)  ·  South Korea (40)  ·  United Kingdom (38)  ·  Australia (34)  ·  Spain (32)  ·  France (30)  ·  Germany (29)  ·  Italy (27)  ·  Taiwan (27)  ·  Canada (22)  ·  Japan (22)  ·  Hong Kong (21)  ·  Malaysia (20)  ·  Argentina (19)

Top investigators

Jicheng Lv (3)  ·  Radko Komers, MD, PhD (3)  ·  Connie L Davis, MD (2)  ·  Eric Michael, MD (2)  ·  Hong Zhang (2)  ·  Jingyuan Xie (2)  ·  Li Li, MD (2)  ·  Xueqing Yu, MD (2)  ·  Zongpei Jiang, M.D. & Ph.D. (2)

Results publications

PMID 38299639, PMID 38864363, PMID 26032537, PMID 26630142, PMID 37772889, PMID 28763548, PMID 40465397, PMID 10093981, PMID 18930568, PMID 28341274, PMID 35675911, PMID 37254256, PMID 37528520, PMID 38724717, PMID 39331470, PMID 39455063, PMID 39899371, PMID 40482854, PMID 40938675, PMID 41442197, PMID 42275148, PMID 42384439, PMID 10676716, PMID 11877568, PMID 14694168, PMID 15851648, PMID 16014059, PMID 17533019, PMID 17699247, PMID 17978307, PMID 18436082, PMID 18587715, PMID 19571790, PMID 19571791, PMID 19628647, PMID 20843592, PMID 21606384, PMID 21680850, PMID 21852672, PMID 22075320, PMID 22722778, PMID 22995802, PMID 23675422, PMID 23782179, PMID 23787555, PMID 23977072, PMID 24009220, PMID 24029421, PMID 24191893, PMID 24641955

NIH funding

2018 (3), 2023 (3), 2014 (2), 2016 (2), 2017 (2), 2005 (1), 2015 (1), 2019 (1), 2025 (1), K23DK093556 (1), R01DK049368 (1)